1. Claudia Ortiz Lopez, PharmD Candidate Cone Health Family Medicine
News You Can Use…
Claudia Ortiz Lopez, PharmD Candidate
Kelsy Combs, PharmD
Pete Koval, PharmD
Cone Health Family Medicine
February, 2017

2. FDA Approval Arymo ER (Morphine Sulfate)
First FDA-approved product that uses Guardian™ Technology
Uses a physical and chemical barrier for abuse deterrence without the use of an opioid antagonist
Increased resistance to cutting, crushing, grinding or breaking compared to non- abuse-deterrent morphine sulfate ER tablets

3. New Epinephrine Injections
Adrenaclick®
Generic Available at CVS
Cash price $110 for a two pack
Auvi-Q®
Available February 14, 2017
Voice guided, needle retraction
$0 out-of-pocket for all commercially insured patients

4. FDA Approval Soliqua™ insulin glargine / lixisenatide
Dose: Single fixed combo 100/33
Combination of a long acting insulin and a GLP-1 in a single, once daily injection

5. 2017 ACP/AAFP Hypertension Update – New “Goals”
Consider drug therapy in adults ≥60 years with a history of stroke or TIA to achieve BP <140 to reduce risk of recurrent stroke
Consider drug therapy in adults ≥60 years at high CV risk* to achieve BP < 140 to reduce risk of stroke or cardiac events
* High CV risk is: “based on individual assessment”

6. FDA Approval from TEVA AirDuoTM RespiClick®
(fluticasone propionate and salmeterol inhalation powder)
Same active ingredients as Advair®
ArmonAirTM RespiClick®
(fluticasone propionate inhalation powder)
Same active ingredients as Flovent®

7. FDA Approval Trulance (plecanatide) Class: guanylate cyclase-C agonist
For the treatment of chronic idiopathic constipation in adults
Dose: 3 mg tablet once daily
ADE: diarrhea

8. Brand-to-OTC
Xyzal Allergy 24HR® levocetirizine dihydrochloride is now available OTC
Forms available in Spring 2017:
5 mg tablets
0.5 mg/mL oral solution

9. PCSK9 Clinical Outcome Trial
“Amgen announces Repatha® (Evolocumab) significantly reduced risk of CV events in FOURIER outcomes study”
Results will be available March 17th, 2017